Life Sciences Group,Inc
Life Science Pharmaceuticals (LSP) develops novel therapeutics to treat cancer, diabetes, and other serious illnesses, with a diverse portfolio of product candidates in pre-clinical and clinical development. The company fosters close relationships with academic institutions and collaborates with international pharmaceutical companies. LSP has licensing agreements with prestigious institutions and companies such as The Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, Dana Farber Cancer Center, MIT, and AbbVie. The company's mission is to develop drugs for unmet medical needs, particularly in oncology, leveraging innovative research and strategic collaborations.
Industries
Nr. of Employees
small (1-50)
Products
Tumor-selective monoclonal antibody targeting an EGFR transitional epitope
A monoclonal antibody that selectively binds a tumor-exposed epitope of the epidermal growth factor receptor and has been characterized for tumor specificity, internalization and payload delivery potential.
Antibody-drug conjugate for EGFR-expressing tumors
An ADC constructed to remain stable in circulation and selectively release cytotoxic agent inside targeted tumor cells; investigated in glioblastoma and squamous cell tumor models and clinical studies.
Tumor-selective monoclonal antibody targeting an EGFR transitional epitope
A monoclonal antibody that selectively binds a tumor-exposed epitope of the epidermal growth factor receptor and has been characterized for tumor specificity, internalization and payload delivery potential.
Antibody-drug conjugate for EGFR-expressing tumors
An ADC constructed to remain stable in circulation and selectively release cytotoxic agent inside targeted tumor cells; investigated in glioblastoma and squamous cell tumor models and clinical studies.
Services
Negotiation, execution and management of licensing agreements and strategic collaborations between academic institutions and pharmaceutical partners for therapeutic candidates.
Negotiation, execution and management of licensing agreements and strategic collaborations between academic institutions and pharmaceutical partners for therapeutic candidates.
Expertise Areas
- Monoclonal antibody therapeutics
- Antibody-drug conjugate development
- Preclinical in vivo efficacy testing
- Early-phase clinical trial management
Key Technologies
- Monoclonal antibodies
- Antibody-drug conjugates (ADC)
- Epitope mapping
- Immunohistochemistry (IHC)
News & Updates
Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).
Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).